Current Suspected Overdose Deaths in Delaware for 2019: Get Help Now!
Maintenance to this site will cause limited access to pages Tuesday, July 23, from 5 to 8 p.m.
As a result of collaborative efforts with public health and government officials, Novartis has additional supplies of rabies vaccine for distribution. However, supplies are still limited to ordering on a per patient basis. Though Novartis is now able to deliver RabAvert vaccine for post-exposure prophylaxis without supply restrictions (no password is required), providers are strongly urged to consult with the rabies program on all cases of potential rabies exposure before treatment is instituted. The Novartis product identification number has changed from 53905-501-01 to 63851-501-01. Questions regarding the Novartis product can be directed to Novartis customer service at 1-800-244-7668.
Sanofi Pasteur continues to have IMOVAX vaccine available for post-exposure prophylaxis. To obtain IMOVAX rabies vaccine providers must first contact the Rabies program at 302-744-4545 so that a risk-assessment can be conducted for the suspected exposure. If the Rabies program determines that rabies post-exposure prophylaxis is indicated they will provide a pass-code to be placed on the Sanofi Pasteur Rabies Post-Exposure Form. The form must be filled out in its entirety, including the required physician's signature and pass code provided by the Rabies program. Please contact Sanofi Pasteur at 1-800-VACCINE to obtain the required form.
Please call the Rabies program (302-744-4545) for information relating to pre exposure prophylaxis.
Additional rabies vaccine information is also available at http://www.cdc.gov/rabies/